Please assess the completion status of the following clinical trial:

Trial Title: Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Patients with hematologic malignancies for whom conventional myeloablative allogeneic stem cell transplantation is deemed clinically appropriate and who are eligible for conventional myeloablative allogeneic stem cell transplantation on treatment plans/protocols, including any of the following:~  * Non-Hodgkin lymphoma or Hodgkin lymphoma (relapsed or refractory disease)~ * Chronic lymphocytic leukemia (received more than one previous treatment regimen)~ * Acute myelogenous or lymphoblastic leukemia (AML/ALL) (high-risk disease, in first complete remission \[CR1\] or subsequent remission, or primary refractory disease)~ * Chronic myelogenous leukemia in tyrosine-kinase resistant chronic phase, accelerated or blast phase, or primary refractory disease~ * Myelodysplastic syndromes in International Prognostic Scoring System (IPSS) high-intermediate or high-risk groups~ * Other hematologic disorders for which allogeneic stem cell transplantation is appropriate (e.g., myelofibrosis)~* Patients who have relapsed after standard autologous and/or allogeneic bone marrow transplant are eligible~* Must be receiving filgrastim (G-CSF)-mobilized related or unrelated donor allogeneic peripheral blood stem cells~  * Patients receiving hematopoietic stem cells of any other sources such as a marrow graft or umbilical cord blood will not be eligible for this study~* Donor must be HLA-genotypically or phenotypically 6 of 6 antigen matched (at the A, B, DR loci) related or unrelated~PATIENT CHARACTERISTICS:~Inclusion criteria:~* Patients with a currently active second malignancy other than non-melanoma skin cancers can only be registered if survival from the second malignancy is expected to be more than 1 year~* Ejection fraction ≥ 45% by either radioisotope Multiple Gated Acquisition Scan (MUGA) scan or Echocardiogram (ECHO)~* Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) ≥ 50% of predicted with no symptomatic pulmonary disease~* Mini Mental Status Exam Score ≥ 20~* Patients must have an expected life expectancy of at least 3 months~* Patients with symptomatic visceral, blood stream or nervous system opportunistic infection are eligible if the infection has been appropriately treated and controlled~  * Patients with a fungal infection must have had treatment for at least one month and must have proof of regression of the infection prior to enrollment~ * Patients may be on antibiotics at the time of transplant~Exclusion criteria:~* Human Immunodeficiency Virus (HIV) infection~* Uncontrolled diabetes mellitus~* Active congestive heart failure from any cause~  * Previous history of congestive heart failure allowed~* Active angina pectoris~* Oxygen-dependent obstructive pulmonary disease~* Failure to demonstrate adequate compliance with medical therapy and follow-up~* Known history of Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency or history of hemolysis indicative of G6PD deficiency~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rasburicase Group (Type: EXPERIMENTAL): Myeloablative (bone marrow depletion) conditioning protocol as per standard of care at the investigator's discretion followed by granulocyte colony-stimulating factor (GCSF)-mobilized human leukocyte antigen (HLA)-matched, related or unrelated donor allogeneic peripheral blood stem cells (unmanipulated), standard graft-versus-host disease (GVHD) prophylaxis as per standard of care at the investigator's discretion and rasburicase 0.20 mg/kg/day administered by intravenous infusion for 5 consecutive days. If after 5 days of rasburicase the participant's uric acid plasma level remains above 5 mg/dL, rasburicase may be continued for up to 7 days in total.
- Control Group (Type: OTHER): Historical chart review of patients from the Blood and Marrow Transplant database who received myeloablative allogeneic stem cell/bone marrow transplantation followed by standard GVHD prophylaxis in the past 10 years. Participants received allopurinol per institutional guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).